Review decisions - Drug and Health Products Portal

Showing 200 results of 292 total

Summary Safety Review - Levetiracetam and Methotrexate - Assessing the Potential Risk of Drug-Drug Interaction

https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00128

Issued / Original Publication Date: 2016-10-24

Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Urinary Retention

https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00121

Issued / Original Publication Date: 2016-10-21

Summary Safety Review - Incretin-Based Therapies - Assessing the Potential Risk of Pancreatic Cancer

https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00126

Issued / Original Publication Date: 2016-10-21

Summary Safety Review - GILENYA (fingolimod) - Assessing the Risk of the Abnormal Tissue Growth (Cancer)

https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00141

Issued / Original Publication Date: 2016-10-19

Summary Safety Review - Gabapentin - Assessing the Potential Risk of Serious Breathing Problems

https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00103

Issued / Original Publication Date: 2016-09-16

Summary Safety Review - SOLIRIS (eculizumab) and BEXSERO (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) - Assessing the Potential Risk of Hemolysis and Low Hemoglobin in Patients Treated with Soliris and Vaccinated with Bexsero

https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00104

Issued / Original Publication Date: 2016-09-16

Summary Safety Review - Viscous Lidocaine 2% - Assessing the Potential Risk of Severe Side Effects in Infants and Young Children

https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00105

Issued / Original Publication Date: 2016-08-29

Summary Safety Review - Bortezomib (VELCADE and generics) - Assessing the Potential Risk of Flesh-Eating Disease (Necrotizing Fasciitis) - UPDATE

https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00106

Issued / Original Publication Date: 2016-08-26

Summary Safety Review - Lanoxin, Toloxin, Apo-digoxin, PMS-digoxin, (Digoxin) - Assessing the Potential Higher Risk of Death Compared to Patients not Using Digoxin

https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00107

Issued / Original Publication Date: 2016-08-23

Summary Safety Review - GILENYA (fingolimod) - Assessing the Potential Risk of a Rare Brain Infection (Progressive Multifocal Leukoencephalopathy)

https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00108

Issued / Original Publication Date: 2016-08-19